1	Tuberculosis presentation and outcomes in elderly Hispanics from Tamaulipas, Mexico
2	
3	Belinda A. Medrano ¹ , Miryoung Lee ¹ , Gretchen Gemeinhardt ² , Javier E. Rodríguez-Herrera ³ ,
4	Moncerrato García-Viveros ³ , Blanca I. Restrepo ^{1,4,5,*}
5	
6	¹ Department of Epidemiology, Human Genetics and Environmental Sciences, School of Public
7	Health, University of Texas Health Science Center at Houston, Brownsville campus,
8	Brownsville, TX, USA
9	² Department of Management, Policy and Community Health, School of Public Health,
10	University of Texas Health Science Center at Houston, Houston, TX, USA
11	³ Secretaría de Salud de Tamaulipas, Reynosa 88630, Matamoros 87370 and Ciudad Victoria,
12	Tamaulipas, México
13	⁴ Population Health Program, Texas Biomedical Research Institute, San Antonio, TX, USA
14	⁵ School of Medicine, South Texas Diabetes and Obesity Institute, University of Texas Rio
15	Grande Valley, Edinburg, TX, USA
16	
17	* Corresponding author: 1214 W. Schunior, UTRGV-EREBL Bldg, Edinburg, TX 78541
18	Blanca.i.restrepo@uth.tmc.edu; Tel.: +01-956-279-3841
19	
20	Running title: Tuberculosis treatment outcomes in elderly Hispanics
21	
22	
72	
23	

24 Abstract

25	Old people are at high risk of developing and dying from pulmonary infections like tuberculosis
26	(TB), but they are few studies and particularly in Hispanics. To address these gaps, we sought to
27	identify host factors associated with TB and adverse treatment outcomes in old Hispanics by
28	conducting a secondary analysis of TB surveillance data from Tamaulipas, Mexico (2006-2013;
29	n=8,381). Multivariable logistic regressions were assessed for the elderly (ELD, \geq 65 years)
30	when compared to young (YA, 18 to 39 years) and middle-aged adults (MAA, 40 to 64 years).
31	We found that the ELD had features associated with a less complicated TB (e.g. less extra-
32	pulmonary TB, abandoning of treatment or having drug resistant TB), and yet, were more likely
33	to die during TB treatment (adj-OR 3.9, 95% 2.5, 5.25). Among the elderly, excess alcohol use
34	and low BMI increased their odds of death, while diabetes and BCG vaccination were protective.
35	These data suggest that old people share some, but not all the risk factors for adverse TB
36	treatment outcomes, when compared with younger adults. Furthermore, even though old age in
37	itself is an important predictor of death during TB, the elderly are not prioritized by the World
38	Health Organization for latent TB infection screening and treatment during contact
39	investigations. We propose the inclusion of the elderly as a high-risk group in TB management
40	guidelines.

41

42 Keywords: tuberculosis, Hispanics, older people, elderly, gerontology, diabetes, BCG, BMI,
43 treatment outcomes

44 Introduction

45	Mycobacterium tuberculosis is a bacterial disease that has infected a quarter of the world's
46	population with non-symptomatic latent infection or progressed to active tuberculosis (TB)
47	disease. In 2020, an estimated 9.9 million people developed TB and 1.5 million died [1]. Latent
48	TB infection and active TB disease are more prevalent in the elderly, i.e., adults over the age of
49	65 [2-4]. This is relevant as the global elderly population grows from 1 out of 11 in 2019 to 1 in
50	6 by 2050 [5]. The World Health Organization (WHO) regions of the Eastern Mediterranean,
51	South-East Asia, and Western Pacific already have a significant burden of TB cases in the
52	elderly populations with Taiwan anticipating almost 80% of their new TB cases in the elderly by
52 53	elderly populations with Taiwan anticipating almost 80% of their new TB cases in the elderly by 2035 [2, 6].
53	2035 [2, 6].
53 54	2035 [2, 6]. The elderly face additional risks of TB reactivation and infection compared to younger adults,
53 54 55	2035 [2, 6]. The elderly face additional risks of TB reactivation and infection compared to younger adults, such as compromised immunity, comorbid conditions, and increased TB exposures due to
53 54 55 56	2035 [2, 6]. The elderly face additional risks of TB reactivation and infection compared to younger adults, such as compromised immunity, comorbid conditions, and increased TB exposures due to clustering in nursing homes [7-9]. TB and general mortality are highest in the elderly group [2,
53 54 55	2035 [2, 6]. The elderly face additional risks of TB reactivation and infection compared to younger adults, such as compromised immunity, comorbid conditions, and increased TB exposures due to

and 95% reduction in TB incidence and deaths, respectively, by 2035 [1, 8, 10, 11].

Despite their high vulnerability, TB in the elderly is understudied, and the available literature is
mostly from Asian populations, with few in Hispanics [12-14]. Studies in Latin American
Hispanics are warranted given that risk factors for TB such as poverty, migration, homelessness,
incarceration, and diabetes have increased in the last decade [15, 16]. Even in a high-income
country like the United States, the TB case rate is nine times higher for Hispanics than for nonHispanic whites (Centers for Disease Control and Prevention [17].

Given the impact of old age on TB elimination efforts, it is important to study the elderly TB
group with the goals of improving patient outcomes and preventing additional TB cases. To
address this knowledge gap, and particularly among Hispanics, we aimed to identify
sociodemographic and medical risk factors and secular trends for TB in the elderly from the state
of Tamaulipas in northeastern Mexico. We also sought to identify the risk factors associated with
adverse treatment TB outcomes in old age.

72 Materials and Methods

73 Study Population

We conducted a secondary analysis of existing TB surveillance data on adults ages 18 to 99 74 75 years with a new TB diagnosis and who were reported to the state of Tamaulipas, Mexico 76 between 2006 and 2013. The state's TB program surveillance dataset was described previously [18]. Briefly, the Tamaulipas's TB surveillance dataset was comprised of 12,748 TB patients 77 78 enrolled between 2005 and 2013, and we excluded repeat episodes from the same subject 79 (n=1,827), individuals less than 18 years old (n=624), recurring TB cases (n=777), and 80 individuals enrolled in 2005 who had poor data quality (n=1,089). This left 8,431 new adult TB patients [18]. For this study, we further excluded 43 individuals identified as having a previous 81 TB episode and seven with missing data on TB treatment outcomes, for a final sample size of 82 83 8,381 TB patients. Patient data was deidentified and the protocol was approved from the Internal Review Board from UTHealth Houston (HSC-SPH-15-0489) and the Secretaría de Salud de 84 Tamaulipas (076/2015/CEI). 85

86 Participant Characteristics

87	We compared the elderly group (65 yrs. or older, ELD) to young adults (18-39 yrs., YA) or
88	middle-aged adults (40-64 yrs., MAA). Sociodemographic variables included age, sex,
89	education, Bacille Calmette-Guerin (BCG) vaccination at birth based on the presence of a BCG
90	scar, self-reported excess alcohol use or intravenous (IV) drug use, and low body mass index
91	$(BMI < 18.5 \text{ kg/m}^2 \text{ at the time of TB diagnosis})$. Comorbidities included chronic obstructive
92	pulmonary disease (COPD), self-reported diabetes, and self-reported or laboratory-confirmed
93	HIV. Variables related to TB at the time of diagnosis included disease location (extrapulmonary
94	or pulmonary), positive acid-fast bacilli (AFB) on sputum smears, diagnosis method [culture
95	confirmation by isolation of <i>M. tuberculosis</i> , positive AFB smears only, or in their absence, a
96	combination of clinical, epidemiological, radiological and/or histopathological findings], and the
97	number of close contacts. In Mexico, drug susceptibility testing is limited to patients with high
98	suspicion of drug-resistant TB with results available for isoniazid (INH), rifampin (RIF),
99	pyrazinamide (PZA), streptomycin (STR), and ethambutol (EMB). Mycobacterium tuberculosis
100	was classified as drug resistant (DR-TB) if resistant to any of the five TB drugs and multi-drug
101	resistant (MDR-TB) when at least INH and RIF were resistant. The adverse outcomes of interest
102	included TB treatment failure (positive AFB smears after five months of TB treatment),
103	abandoned treatment (lost during follow-up for more than three months), and death due to any
104	cause during TB treatment.

105 Statistical Analyses

106 Two-group comparisons of binary variables were analyzed by Pearson's chi-square or Fisher's

107 exact test and the Student's-t test was used for mean comparisons between two groups.

108 Increasing or decreasing trends across age groups or across time were established by the score

109 test for the trend of odds for binary variables. To conduct comparisons between-group, trends

110	across age groups, and trends across time for polytomous and numerical variables, we used the
111	nptrend command in STATA, which is a nonparametric test for trends across ordered groups (an
112	extension of the Wilcoxon rank-sum test). For multiple logistic regressions models, we used
113	backward selection with consideration of variables with p values less than 0.20 in bivariable
114	analysis, and keeping age and sex as key sociodemographics in final models. Effect
115	modification variables for age and each predictor variable were included in simple logistic
116	regression models for adverse outcomes, to determine if age modifies the observed effect of each
117	predictor variable. Statistical significance was set at Type I error (alpha) level <0.05. Data
118	analysis was performed using STATA IC (Stata Corp LLC, College Station, TX) 14.

119 **Results**

120 Sociodemographics and Comorbidities in the Elderly

121 The characteristics of the 8,381 TB patients for analysis are described in **Table 1**. Their mean

age was 43 years (SD 16.6; range 18 to 97). Males comprised 65.5% of all TB patients. Less than

half (42.2%) had a high school degree or higher education, three-fourths (76.2%) had a history of

BCG vaccination, 5.6% reported excess alcohol use, 0.5% were IV drug users, and 8.3% had low

BMI. The most prevalent comorbidity was diabetes (25.2%), followed by HIV (5.3%) and

126 COPD (0.9%).

127 The distribution of TB patients by age group was: 46% in YA, 42% in MAA, and 12% in ELD.

Mean ages for YA, MAA, and ELD TB patient groups were 28 (SD 6.2), 50 (SD 6.9), and 73

129 (SD 6.5) years, respectively. The ELD differed from the two younger age groups in their lower

level of education (high school degree or higher in 10.9% in ELD vs 56.9% in YA or 35.5% in

131 MAA), BCG vaccination (48.8% in ELD vs 83.6% in YA and 75.7% in MAA), and IV drug use

- 132 (0.1% in ELD vs 0.8% in YA). Accordingly, significant trends with older age (from YA to MAA
- to ELD) included a decrease in education level, BCG vaccination rates, and IV drug use, trend p
- 134 <0.001 for all. Low BMI was highest in the ELD (10.3%) followed by YA (9.3%) and MAA
- 135 (6.6%).
- 136 For comorbidities, COPD was more common among the ELD (4.1% in ELD vs 0.1% in YA and
- 137 0.7% in MAA; p <0.001 for increasing trend with older age). Diabetes increased with older age
- 138 (trend p < 0.001), although MAA had the highest prevalence (40%), with the ELD having 31.9%
- and YA 10% (p <0.001). HIV prevalence was lowest in the ELD (0.5% in ELD vs 7.7% YA and
- 140 4.0% in MAA; p <0.001 for decreasing trend with older age).

141 **TB-related Characteristics**

- 142 Most patients had pulmonary TB (92%) and a positive AFB smear at the time of diagnosis
- 143 (85.1%; **Table 1**). Cultures are not routinely performed in Tamaulipas, and hence, the diagnosis
- 144 was mostly based on smear results (79.1%), with only 6.8% being culture-confirmed. Each TB
- 145 patient had an average of 3.7 close contacts. When compared to YA, the ELD had less extra-
- pulmonary TB (ELD 6.0% vs YA 9.4%; decreasing trend p <0.001) or culture-confirmed TB
- 147 (ELD 5.5% vs YA 8.0%). The ELD had the highest mean number of close contacts (ELD 4.1 vs

148 3.7 in YA or 3.6 in MAA).

149 **TB Drug Resistance**

Drug susceptibility testing was only available for 1,165 (13.9%) TB patients, with more testing
in YA (15.4%) and MAA (14.2%) vs. the ELD (7.3%; trend p <0.001; Table 2). For primary
analysis, we assumed that the absence of susceptibility results indicated drug-susceptible TB

since testing is prompted when DR-TB is suspected (Table 2). We found that DR-TB decreased
with age (trend p=0.030). Among all age groups, the highest monoresistance was for INH
(1.2%), and across age groups, only INH monoresistance showed a decreasing trend with age
(p=0.002). MDR-TB occurred in 0.6% of all patients and did not differ across age groups.
Similar analysis but limited to isolates tested for drug resistance provided similar findings (S1

158 **Table**).

159 Adverse TB Treatment Outcomes

Among all patients, 14.9% had one of the following adverse outcomes: treatment failure (1.9%),

abandoned treatment (6.9%), or death (6.2%), **Table 1**. Adverse TB treatment outcomes were

highest among the ELD (20.1%) followed by YA (15.4%) and MAA (12.9%) groups. Treatment

163 failure did not differ between age groups, but the ELD group was less likely to abandon

treatment (4.3%) when compared to YA (9.2%; p < 0.001) with a decreasing trend with older age

(trend p <0.001). In contrast, the ELD were more likely to die during TB treatment (13.6%)

when compared to YA (4.5%) or MAA (5.8%) with an increasing trend with older age (trend p

167 <0.001).

168 For multivariable analysis, we examined whether old age was independently associated with

adverse TB treatment outcomes with YA as the reference group. IV drug use and HIV were

170 excluded as predictor variables due to their low prevalence in the ELD group (**Table 3**). Age

171 groups were not associated with treatment failure. Instead, among all age groups, adjusted

172 models showed that treatment failure was higher for males, although statistical significance was

not reached (adj. OR 1.45, 95% CI 0.99, 2.10), those with positive AFB smears (adj. OR 1.97,

174 95% CI 1.03, 3.79) or DR-TB, (adj. OR 13.85, 95% CI 9.42, 20.37). Higher education was

175	protective against treatment failure (adj. OR 0.69, 95% CI 0.48, 0.99). Abandoning treatment
176	was 59% lower in the elderly (adj. OR 0.41, 95% CI 0.28, 0.59) when compared to YA (Table
177	3). Among all TB patients, the factors associated with higher odds of abandoning treatment were
178	male sex (adj. OR 2.09, 95% CI 1.65, 2.66), excess alcohol use (adj. OR 1.44, 95% CI 1.03,
179	2.01), and low BMI (adj. OR 1.59, 95% CI 1.18, 2.13). Protective factors against abandoning
180	treatment included high school or higher education (adj. OR 0.74, 95% CI 0.60, 0.90), having
181	extrapulmonary disease (adj. OR 0.51, 95% CI 0.30, 0.87), and positive AFB smear at diagnosis
182	(adj. OR 0.63, 95% CI 0.49, 0.82). The odds of abandoning treatment decreased by 11% (adj.
183	OR 0.89, 95% CI 0.85, 0.93) for each additional close contact reported by a TB patient. Death
184	was four-fold higher with old age (ELD vs YA: adj. OR 3.90, 95% CI 2.90, 5.25; Table 3).
185	Among all TB patients, the odds of death were also higher for MAA (adj. OR 1.62, 95% CI 1.25,
186	2.09), males (adj. OR 1.59, 95% CI 1.24, 2.04), excess alcohol users (adj. OR 1.66, 95% CI 1.15,
187	2.39), those with low BMI (adj. OR 2.14, 95% CI 1.60, 2.87), and extrapulmonary disease (adj.
188	OR 1.94, 95% CI 1.29, 2.91). BCG vaccination (adj. OR 0.67, 95% CI 0.53, 0.85), diabetes (adj.
189	OR 0.59, 95% CI 0.44, 0.78), and positive AFB smear (adj. OR 0.63, 95% CI 0.47, 0.84) were
190	protective against death.

191 We sought to identify independent predictors of adverse outcomes among the ELD group alone

192 (S2 Table). In the ELD, the odds of treatment failure was 14 times higher in patients with DR-

193 TB (adj. OR 14.10, 95% CI 4.69, 42.32). Abandoning treatment decreased by 56% for those with

a positive AFB smear and by 15% for each close contact. The odds of death increased by 4% for

- each additional year of life, and by more than 2-fold in those with excess alcohol use or low
- 196 BMI. Male sex was not associated with any adverse outcome in the ELD (S2 Table), despite its
- 197 relationship with treatment failure, abandoning treatment and death in all age groups (**Table 3**).

198 Finally, we evaluated if among all TB patients, age would modify the associations between host

- 199 factors and adverse TB treatment outcomes. However, multivariable models with additional
- 200 interaction terms for age did not show significant associations (S3 Table).

201 Trends Over the Eight-year Period in the ELD

- 202 We evaluated if there were trends over time (2006 -- 2013) in the prevalence or characteristics of
- the ELD group. Among all TB patients, the proportion of ELD remained similar across the years
- (range 11.2 13.8%; p 0.531; **S4 Table**). Among the ELD group only, there was an increasing
- trend in education level (p < 0.001), BCG vaccination (p < 0.001), diabetes (p 0.010),
- extrapulmonary TB (p 0.005) and DR-TB (p 0.002; Tables 4 and S4). We also evaluated trends
- 207 over time for younger adults (Table 4) and found that unlike the ELD, the YA and MAA had a
- reduction in excess alcohol use, low BMI, and abandoning of TB treatment, and that the YA hada decreasing trend in death.

210 **Discussion**

Despite projections showing a worldwide increase in the proportion of older individuals, studies 211 in the elderly are underrepresented when compared to those in younger adults [19-21]. This 212 213 knowledge gap extends to the elderly with TB, especially in the Americas. To address this 214 disparity, we sought to obtain a better understanding of elderly Hispanics with TB using TB surveillance data from the Mexican state of Tamaulipas. The elderly comprised 12.3% of all 215 adult TB patients, and over the eight-year study period we observed: i) an improvement in 216 217 factors that could be protective for TB (e.g. higher education and BCG vaccination coverage), ii) an increase in factors that favor adverse TB outcomes (e.g. extrapulmonary TB and DR-TB), and 218

219	iii) an increase in diabetes, which had a protective effect on TB outcomes in our ELD cohort as
220	discussed below [22-26]. The elderly differed from younger adults in their higher prevalence of
221	COPD, which could increase their odds of a more severe TB disease, and in having less BCG
222	vaccination and lower education level, which have been associated with higher odds of TB [14,
223	27, 28]. However, old age was also associated with factors known to improve their TB prognoses
224	such as less IV drug use, HIV, and extra-pulmonary TB, and abandonment of treatment [29-31].
225	The distribution of risk factors for TB, therefore, can have variations across all adult age groups
226	and identifying the high-risk profiles in the elderly is important for prompt TB suspicion,
227	diagnosis, and treatment initiation, in order to improve their prognosis.
228	Regardless of a combination of risk and protective factors for TB in the elderly in multivariable
229	models, the highest threat to this age group was their higher odds of death. This finding is
230	consistent with previous studies in the elderly, and we now report it in our Hispanic TB patients
231	[9, 32]. And among the elderly with TB, death was associated with an increase in age, excess
232	alcohol use and low BMI. These factors also contribute to the higher odds of death in all adult
233	age groups [1, 2, 25, 33, 34]. In contrast, male sex was a risk factor for death in YA and MAA
234	TB patients, but not in the ELD in our study.
235	The prevalence of type 2 diabetes increases with age, as observed in our TB cohort [35, 36].
236	Diabetes is a risk for TB in adults, this includes findings using prospective or retrospective
237	cohorts from Hispanics in US and Mexican communities [18, 37, 38] but not in older people [13,

14]. We posit that differences between diabetes in younger versus older adults may be explained

- by differences in the pathophysiology and/or the management of type 2 diabetes [13]. While
- 240 diabetes in the elderly may not be a risk factor for TB development, in the present study, we
- evaluated if it would be associated with higher odds of death. We found the opposite, with

diabetes being protective, as reported in Brazil by [39]. A higher risk of adverse TB treatment 242 outcomes in the presence of diabetes has been reported in previous studies, although not 243 244 specifically evaluated in older patients [9, 25, 40]. A possible explanation for these discrepant findings may be the higher prevalence of obesity in diabetes patients. While diabetes is a risk 245 factor for TB, obesity is protective against TB [41, 42]. It is possible that the higher prevalence 246 247 of obesity in our study population offsets, to some extent, the risk of death during TB that is conferred by diabetes [43]. Consistent with this finding, a study in adults from India reported that 248 249 diabetes offsets the risk of adverse outcomes conferred by low BMI [44]. Further studies are 250 needed to understand the relationship between diabetes, BMI, death in TB patients, and old age. 251 We found that BCG vaccination at birth decreased with older age. This is consistent with the 252 lower prevalence of BCG vaccination in the elderly versus younger adults with TB in a prospective research cohort [14]. In that study, BCG vaccination at birth was associated with 253 lower odds of TB, but only in the elderly. This finding was intriguing given that BCG is known 254 255 to protect infants and young children from TB, but not adults [1]. Here we find that BCG vaccination at birth is associated with lower odds of death from TB in all age groups. Our 256 257 findings are consistent with the association between unfavorable TB treatment outcomes and 258 absence of a BCG scar in a Malaysian population [25]. Together, these findings suggest a possible protective role of BCG with respect to TB risk or death, although further studies are 259 260 needed to rule out confounding factors that were not available in the surveillance dataset, such as 261 lower access to healthcare in non-BCG-vaccinated individuals. At the cellular level, BCG vaccination induces epigenetic changes in innate immune cells (e.g., trained immunity) that 262 263 associate with protection against TB and other microbial infections [45]. Thus, basic science

studies are also warranted to help elucidate how BCG vaccination at birth may contribute to TBprotection and lower the risk of death in the elderly.

266 We found a decreasing prevalence of extrapulmonary TB with older age, which is consistent

with previous studies [31, 46]. These age-related differences may be due to a lower prevalence of

comorbidities like HIV, when compared to younger TB patients, that favor extrapulmonary

disease [31, 46, 47].

270 Abandonment of treatment contributes to adverse outcomes but we found that the ELD are less

271 likely to abandon TB treatment [30, 48, 49]. Interestingly, we found an inverse association

between the number of TB contacts and odds of abandoning treatment in all age groups, or

among ELD patients only. Further studies are needed to determine if this finding is consistent

with reports indicating that the level and quality of social support received by patients affects

their health outcomes and adherence to treatments [50-53].

276 Patients with drug-resistant TB are more likely to have adverse treatment outcomes [1, 49, 54,

55]. While we found a lower prevalence of DR-TB in the ELD, our findings point to the

importance of identifying these patients given their higher odds of treatment failure.

Our large sample size, coverage over an eight-year period, and breakdown of age into three

groups, allowed for an in-depth cross-sectional assessment of unique features in ELD TB

281 patients with respect to their sociodemographics, comorbidities, TB characteristics, and

treatment outcomes. Limitations included the secondary nature of the data analyses. Diabetes

283 diagnosis and duration of disease, excess alcohol use, and, to some extent, HIV status were self-

reported and may be underestimated, although we do not anticipate that there would be a

differential underreporting of these host characteristics in the ELD when compared to other age

groups. Low BMI was reported as a categorical variable with no further granularity to assess the contribution of different levels of body weight or obesity to TB risk or protection in the elderly. Smoking is a risk factor for TB and known to be more prevalent in older cohorts, but not reported in this surveillance dataset [14]. Finally, DR-TB testing was only evaluated upon suspicion, as in most TB-endemic countries worldwide, and hence, pan-susceptibility was assumed when data was not available. However, analysis limited to patients in whom drug susceptibility was tested provided similar results (**Table S1**).

293 Our study raises awareness of the high vulnerability of older people to death from TB. Per 294 WHO's latent TB infection management guidelines, TB contact investigations focus on the identification of high-risk groups for TB development. However, these are limited to children 295 296 below 5 years of age or people living with HIV, and of other adults and children household contacts in low TB incidence countries without mention of the growing elderly population [56]. 297 298 Our findings call for the need to consider the elderly in a similar high-risk category. A recent 299 study showed that Interferon-gamma release assays (IGRA) are effective for identification of 300 latent TB infection in the elderly [57]. We also identified modifiable sociodemographic factors 301 associated with higher odds of death during TB in the elderly, such as excess alcohol use or low 302 BMI. Close supervision of elderly with new TB or LTBI should be offered for counseling of 303 alcohol use or nutritional support. We also found that abandoning treatment was more likely 304 when patients have fewer contacts. Hence, protocols to promote social workers at TB clinics to 305 reach out to family members to emphasize the importance of social support, can have a positive impact on treatment success. By studying the elderly TB group separately from the other distinct 306 307 adult age groups, we will have a better understanding of how to approach the challenges of TB eradication in this understudied and vulnerable population. 308

309 Acknowledgements

- 310 We thank the personnel from all the sanitary jurisdictions of the Secretaría de Salud de
- 311 Tamaulipas who contributed to the collection and recording of data from the TB patients, and Dr.
- 312 Santa Elizabeth Ceballos Liceaga for providing the surveillance datasets for our analysis as
- 313 coordinator of the Sistema de Vigilancia Epidemiológica de Tuberculosis y Lepra, Dirección
- General de Epidemiología, Secretaría de Salud de Mexico. We also thank Dr. Bassent Abdelbary
- for generation of the basic dataset used for analysis and guidance for data analysis.

317 **References**

318

- 319 1. World-Health-Organization. Global tuberculosis report 2021.
- 320 <u>https://www.hoint/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-</u>
- 321 <u>2021</u> [Internet]. 2021 2022. Available from: <u>https://www.who.int/teams/global-tuberculosis-</u>
- 322 programme/tb-reports/global-tuberculosis-report-2021.
- 2. Caraux-Paz P, et al. Tuberculosis in the Elderly. J Clin Med. 2021;10(24).
- 324 3. Hochberg NS, Horsburgh CR, Jr. Prevention of tuberculosis in older adults in the United
- States: obstacles and opportunities. Clin Infect Dis. 2013;56(9):1240-1247.
- Li T, et al. Age-Specific Pulmonary Tuberculosis Notification Rates China, 2008-2018.
 China CDC Wkly. 2022;4(38):841-846.
- 328 5. World population aging 2019. New York, NY, USA: United Nations, 2020 2020. Report
 329 No. Available from:
- 330 <u>https://www.un.org/en/development/desa/population/publications/pdf/ageing/WorldPopulationA</u>
 331 <u>geing2019-Report.pdf</u>.
- Ku CC, Dodd PJ. Forecasting the impact of population ageing on tuberculosis incidence.
 PLoS One. 2019;14(9):e0222937.
- 334 7. Chitnis AS, et al. Trends in Tuberculosis Cases Among Nursing Home Residents,
- California, 2000 to 2009. J Am Geriatr Soc. 2015;63(6):1098-1104.

8. Murali S, et al. Comparison of profile and treatment outcomes between elderly and nonelderly tuberculosis patients in Puducherry and Tamil Nadu, South India. PLoS One.
2021;16(8):e0256773.

Negin J, et al. Tuberculosis among older adults--time to take notice. Int J Infect Dis.
2015;32:135-137.

10. Di Gennaro F, et al. Active Pulmonary Tuberculosis in Elderly Patients: A 2016-2019

Retrospective Analysis from an Italian Referral Hospital. Antibiotics (Basel). 2020;9(8).

11. Cheng J, et al. Incidence and risk factors of tuberculosis among the elderly population in

China: a prospective cohort study. Infect Dis Poverty. 2020;9(1):13.

Garcia-Goez JF, et al. Tuberculosis in elderly patients in the city of Cali, Colombia: a
hospital-based cohort study. J Bras Pneumol. 2020;46(5):e20200072.

13. Restrepo BI, et al. Differential Role of Type 2 Diabetes as a Risk Factor for Tuberculosis
in the Elderly versus Younger Adults. Pathogens. 2022;11(12).

Scordo JM, et al. A prospective cross-sectional study of tuberculosis in elderly Hispanics
reveals that BCG vaccination at birth is protective whereas diabetes is not a risk factor. PLoS
One. 2021;16(7):e0255194.

15. Tuberculosis in the Americas. Regional Report 2020. Washington D.C: Pan American

Health Organization (PAHO), 2021 2021. Report No. Available from:

354 <u>https://iris.paho.org/handle/10665.2/55194</u>.

- Ranzani OT, et al. Increasing tuberculosis burden in Latin America: an alarming trend for
 global control efforts. BMJ Glob Health. 2021;6(3).
- 17. CDC. TB and Hispanic or Latino Persons. Centers for Disease Control and Prevention,
- 358 2022 11/22/2022. Report No. Available from:
- 359 <u>https://www.cdc.gov/tb/topic/populations/latino/default.htm.</u>
- 18. Abdelbary BE, et al. Tuberculosis-diabetes epidemiology in the border and non-border
- regions of Tamaulipas, Mexico. Tuberculosis (Edinb). 2016;101S:S124-S134.
- 362 19. Mody L, et al. Recruitment and retention of older adults in aging research. J Am Geriatr
- **363** Soc. 2008;56(12):2340-2348.
- 20. World population aging 2020 Highlights. New York: United Nations, 2020 2020. Report
- 365 No. Available from:
- 366 https://www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/files/files/docu
- 367 <u>ments/2020/Nov/undesa_pd-2020_world_population_ageing_highlights.pdf</u>.
- 368 21. World-Health-Organization. Ageing and health. World Health Organization; WHO, 2022
- 369 10/1/2022. Report No. Available from: <u>https://www.who.int/news-room/fact-</u>
- 370 <u>sheets/detail/ageing-and-health</u>.
- 22. Atif M, et al. Treatment outcomes of extrapulmonary tuberculosis in Bahawalpur,
- Pakistan; a record review. J Pharm Policy Pract. 2020;13:35.

373 23. Gebrezgabiher G, et al. Treatment Outcome of Tuberculosis Patients under Directly

374 Observed Treatment Short Course and Factors Affecting Outcome in Southern Ethiopia: A Five-

375 Year Retrospective Study. PLoS One. 2016;11(2):e0150560.

Koch A, et al. Drug-resistant tuberculosis: challenges and opportunities for diagnosis and
treatment. Curr Opin Pharmacol. 2018;42:7-15.

25. Tok PSK, et al. Determinants of unsuccessful treatment outcomes and mortality among

tuberculosis patients in Malaysia: A registry-based cohort study. PLoS One.

380 2020;15(4):e0231986.

26. Yen YF, et al. Determinants of mortality in elderly patients with tuberculosis: a

population-based follow-up study. Epidemiol Infect. 2017;145(7):1374-1381.

Jain VK, et al. Tuberculosis in the era of COVID-19 in India. Diabetes Metab Syndr.
2020;14(5):1439-1443.

28. Nordholm AC, et al. Social determinants of tuberculosis: a nationwide case-control study,
Denmark, 1990-2018. Int J Epidemiol. 2022;51(5):1446-1456.

29. Lienhardt C. From exposure to disease: the role of environmental factors in susceptibility
to and development of tuberculosis. Epidemiol Rev. 2001;23(2):288-301.

389 30. Mansour G, et al. Factors Related to Non-Adherence and Abandonment of Pulmonary
390 Tuberculosis Treatment. Medicina (Ribeirao Preto). 2021;54(2):e-172543.

391 31. Qian X, et al. Risk factors for extrapulmonary dissemination of tuberculosis and
392 associated mortality during treatment for extrapulmonary tuberculosis. Emerg Microbes Infect.
393 2018;7(1):102.

394 32. Leung EC, et al. Delayed diagnosis of tuberculosis: risk factors and effect on mortality
among older adults in Hong Kong. Hong Kong Med J. 2018;24(4):361-368.

396 33. Rehm J, et al. The association between alcohol use, alcohol use disorders and

tuberculosis (TB). A systematic review. BMC Public Health. 2009;9:450.

398 34. Volkmann T, et al. Tuberculosis and excess alcohol use in the United States, 1997-2012.

399 Int J Tuberc Lung Dis. 2015;19(1):111-119.

400 35. CDC. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the

401 United States. Atlanta, GA, USA: Centers for Disease Control and Prevention, 2022 6/29/2022.

402 Report No. Available from: <u>https://www.cdc.gov/diabetes/data/statistics-report/index.html</u>.

403 36. Mordarska K, Godziejewska-Zawada M. Diabetes in the elderly. Prz Menopauzalny.
404 2017;16(2):38-43.

405 37. Al-Rifai RH, et al. Association between diabetes mellitus and active tuberculosis: A
406 systematic review and meta-analysis. PLoS One. 2017;12(11):e0187967.

407 38. Restrepo BI, et al. Cross-sectional assessment reveals high diabetes prevalence among
408 newly-diagnosed tuberculosis cases. Bull WHO. 2011;89(5):352-359.

oup in						
6.						
PLoS ONE.						
tor for						
/O						
nighlights						
groups.						
Tuberculosis (Edinb). 2018;113:10-18.						
osis						
Nat Rev						
ts, China,						

- 426 47. Shivakoti R, et al. Association of HIV infection with extrapulmonary tuberculosis: a
 427 systematic review. Infection. 2017;45(1):11-21.
- 428 48. CDC. Basic TB facts. Atlanta, GA, USA: Centers for Disese Control and Prevention,
- 429 Division of Tuberculosis Elimination NCfH, Viral Hepatitis, STD, and TB Prevention; 2016
- 430 03/20/2016. Report No. Available from: <u>https://www.cdc.gov/tb/topic/basics/default.htm</u>.

431 49. Trebucq A, et al. Short-Course Regimen for Multidrug-Resistant Tuberculosis: A Decade
432 of Evidence. J Clin Med. 2019;9(1).

- 433 50. Boen CE, et al. Social Relationships, Inflammation, and Cancer Survival. Cancer
- 434 Epidemiol Biomarkers Prev. 2018;27(5):541-549.

435 51. Cayla JA, et al. Tuberculosis treatment adherence and fatality in Spain. Respir Res.
436 2009;10(1):121.

Li X, et al. Effectiveness of comprehensive social support interventions among elderly
patients with tuberculosis in communities in China: a community-based trial. J Epidemiol
Community Health. 2018;72(5):369-375.

- 440 53. World-Health-Organization. Adherence to long-term therapies : evidence for action.
- 441 World Health Organization; WHO, 2003 2003. Report No. Available from:
- 442 <u>https://apps.who.int/iris/handle/10665/42682</u>.

443	54.	Abdelbary BE, et al. Predicting treatment failure, death and drug resistance using a					
444	computed risk score among newly diagnosed TB patients in Tamaulipas, Mexico. Epidemiol						
445	Infect.	2017;145(14):3020-3034.					
446	55.	Giri VP, et al. The Characteristics and Patterns of Drug-Resistant Pulmonary					
447	Tuber	culosis in Eastern India. Trop Med Infect Dis. 2022;7(9).					
448	56.	World-Health-Organization. Latent tuberculosis infection: updated and consolidated					
449	guidel	ines for programmatic management. World Health Organization; WHO, 2018 2018.					
450	Repor	t No. Available from: <u>https://apps.who.int/iris/handle/10665/260233</u> .					
451	57.	Scordo JM, et al. Interferon Gamma Release Assays for Detection of Latent					
452	Mycol	pacterium tuberculosis in Elderly Hispanics. Int J Infect Dis. 2021.					
450							
453							
454 455							
456	Sup	porting Information					
457 458		ble. TB drugs susceptibility sub-analysis that excludes not tested and unknown from resistance calculations.					
459 460		ble. Multivariable analyses for predicting treatment failure, abandoned treatment, eath in the elderly (ELD) group.					
461 462		ble. Evaluation of age as an effect modifier of the association between the predictor bles listed and adverse TB outcomes.					
463 464		ble. Trends over time (2006 – 2013) in the prevalence of the Elderly group or their cteristics.					

	All Adults	YA	MAA	ELD	ELD vs.	ELD vs.	Trend Across
	(≥18 y)	(18 - 39 y)	(40 - 64 y)	(≥65 y)	YA	MAA	Age Groups
Total n (row %)	8381 (100)	3854 (46.0)	3492 (41.7)	1035 (12.3)	p-value ^a	p-value ^a	p-value ^{b, †}
Sociodemographic Characteri	istics						
Age	43 (16.6)	28 (6.2)	50 (6.9)	73 (6.5)			
Male Sex	5493 (65.5)	2554 (66.3)	2287 (65.5)	652 (63.0)	0.049	0.139	0.068
High School or Higher	2205 (12.2)	2002 (56.0)	1104 (25.5)	100 (10 0)	0.001	0.001	
(n=8040)	3395 (42.2)	2093 (56.9)	1194 (35.5)	108 (10.9)	< 0.001	<0.001	↓ <0.001
BCG Vaccination (n=7814)	5955 (76.2)	3052 (83.6)	2453 (75.7)	450 (48.8)	< 0.001	< 0.001	↓ <0.001
Excess Alcohol	473 (5.6)	198 (5.1)	236 (6.8)	39 (3.8)	0.069	< 0.001	0.995
IV Drug Use	39 (0.5)	30 (0.8)	8 (0.2)	1 (0.1)	0.013	0.694	↓ <0.001
Low BMI	696 (8.3)	360 (9.3)	229 (6.6)	107 (10.3)	0.333	< 0.001	0.275
Comorbidities							
COPD	72 (0.9)	5 (0.1)	25 (0.7)	42 (4.1)	<0.001	< 0.001	↑ <0.001
Diabetes	2111 (25.2)	386 (10.0)	1395 (40.0)	330 (31.9)	< 0.001	< 0.001	↑ <0.001
HIV	442 (5.3)	297 (7.7)	140 (4.0)	5 (0.5)	< 0.001	< 0.001	↓ <0.001

Table 1. Descriptive Characteristics of TB Patients by Age Group, Tamaulipas 2006 - 2013

TB Location (n=8380)

Extrapulmonary TB	670 (8.0)	362 (9.4)	246 (7.0)	62 (6.0)	0.001	0.237	↓ <0.001
Pulmonary TB	7710 (92.0)	3491 (90.6)	3246 (93.0)	973 (94.0)			
Positive AFB Smear (n=7683)	6537 (85.1)	2934 (83.7)	2781 (86.1)	822 (86.9)	0.016	0.520	↑ 0.002
TB Diagnosis Type							
Culture confirmation	571 (6.8)	308 (8.0)	206 (5.9)	57 (5.5)	0.017	0.195	0.794
AFB Smear only	6631 (79.1)	2957 (76.7)	2841 (81.4)	833 (80.5)			
Clinical-epidemiological ^c	1145 (13.7)	571 (14.8)	436 (12.5)	138 (13.3)			
Missing	34 (0.4)	18 (0.5)	9 (0.3)	7 (0.7)			
No. of Contacts (n=8103)	3.7 (2.6)	3.7 (2.4)	3.6 (2.5)	4.1 (3.1)	< 0.001	< 0.001	0.220
Adverse treatment Outcomes	1252 (14.9)	592 (15.4)	452 (12.9)	208 (20.1)	< 0.001	<0.001	0.097
Treatment Failure	156 (1.9)	64 (1.7)	69 (2.0)	23 (2.2)	0.225	0.622	0.176
Abandoned Treatment	579 (6.9)	356 (9.2)	179 (5.1)	44 (4.3)	< 0.001	0.253	↓ <0.001
Died	517 (6.2)	172 (4.5)	204 (5.8)	141 (13.6)	< 0.001	< 0.001	↑ <0.001

Note: Data expressed as number (column %) for categorical variables and mean (standard deviation) for continous variables and number of Contacts. Analysis of each variable includes all 8,381 TB patients except when indicated in parenthesis. YA=young adults, MAA=middle-aged adults, ELD=elderly

^a Chi-square test or Fisher's Exact test for categorical variables and Student t test for continuous variables

^b Score test for trend of odds for categorical variables and the nonparametric test for trend across ordered groups, an extension of the Wilcoxon ranksum test, was used for comparing the number of contacts across groups

^c Clinical-epidemiological diagnosis is based on signs and symptoms, epidemiology, radiological and/or histological findings

[†] Trend direction with respect to old age is indicated by arrows preceding the trend p values

Table 2. TB D	rug Resistance	Prevalence by	v Age Group

	All Adults	YA	MAA	ELD	Trend across age groups
	(≥18 y)	(18 - 39 y)	(40 - 64 y)	(≥65 y)	p-value ^{b,†}
Total n	8381	3854	3492	1035	
Tested	1165 (13.9)	593 (15.4)	496 (14.2)	76 (7.3)	↓ <0.001
DR-TB	257 (3.1)	134 (3.5)	99 (2.8)	24 (2.3)	↓0.030
INH	99 (1.2)	57 (1.5)	39 (1.1)	3 (0.3)	↓0.002
RIF	6 (0.1)	4 (0.1)	2 (0.1)	0 (0)	0.238
PZA	6 (0.1)	2 (0.1)	3 (0.1)	1 (0.1)	0.544
STR	36 (0.4)	12 (0.3)	17 (0.5)	7 (0.7)	0.083
EMB	4 (0.1)	3 (0.1)	0 (0)	1 (0.1)	0.633
MDR-TB	54 (0.6)	26 (0.7)	22 (0.6)	6 (0.6)	0.715

Note: Data expressed as n (column %). Total n = Total number of TB patients in each age group. This is the denominator for all calculations where those not tested were considered drug-susceptible as described in the text. YA=young adults, MAA=middle-aged adults, ELD=elderly. Tested = susceptibility testing documented. DR-TB= resistant to any of the TB drugs listed. Mono-resistance is listed for individual antibiotics: INH= isoniazid, RIF= rifampin, PZA= pyrazinamide, STR= streptomycin, EMB= ethambutol. MDR-TB=multi-drug resistant TB defined as resistant to at least INH and RIF.

^a Chi-square or Fisher's Exact test

^b Score test for trend of odds across the three age groups

[†] Trend direction with respect to old age is indicated by arrows preceding the trend p values

treatment fanure, abanuono		it, of death	Aba	ndoned		
	Treatm	ent Failure	Tre	atment	Ι	Died
Predictor Variables	adj. OR	95% CI	adj. OR	95% CI	adj. OR	95% CI
Age Group						
YA (18 - 39 y)	1.00		1.00		1.00	
MAA (40 - 64 y)	1.23	0.85, 1.77	0.49	0.40, 0.61	1.62	1.25, 2.09
ELD (≥65 y)	1.39	0.83, 2.33	0.41	0.28, 0.59	3.90	2.90, 5.25
Sociodemographic Charact	eristics					
Male Sex	1.45	0.99, 2.10	2.09	1.65, 2.66	1.59	1.24, 2.04
High School or Higher	0.69	0.48, 0.99	0.74	0.60, 0.90		
BCG Vaccination					0.67	0.53, 0.85
Excess Alcohol			1.44	1.03, 2.01	1.66	1.15, 2.39
Low BMI			1.59	1.18, 2.13	2.14	1.60, 2.87
Comorbidities						
COPD						
Diabetes					0.59	0.44, 0.78
TB-related Characteristics						
Extrapulmonary TB			0.51	0.30, 0.87	1.94	1.29, 2.91
Positive AFB Smear	1.97	1.03, 3.79	0.63	0.49, 0.82	0.63	0.47, 0.84
No. of Contacts			0.89	0.85, 0.93		
DR-TB	13.85	9.42, 20.37				

Table 3. Multivariable analyses to identify whether old age (ELD) is an independent predictor of treatment failure, abandoned treatment, or death

Note: Predictor variables with a significance level <0.20 were included in the initial full models. Reduced models (shown) include age group plus predictor variables with a significance level <0.05. adj. OR=adjusted odds ratio. CI=confidence intervals, YA=young adults, MAA=middle-aged adults, ELD=elderly

Table 4. Trends across time (20062013) in sociodemographic and clinical characteristics of TB patients	5
by age groups ^{a, †}	

	All Adults	YAA	MAA	ELD
	(≥18 y) 8381	(18 - 39 y) 3854	(40 - 64 y) 3492	(≥65 y)
	(100%)	(46.0%)	(41.7%)	1035 (12.3%)
Sociodemographic Characteristics	5			
Male Sex High School or Higher Education	↓0.043	0.070	0.218	0.982
(n=8040)	↑<0.001	↑<0.001	↑<0.001	↑<0.001
BCG Vaccination (n=7814)	↑<0.001	↑<0.001	↑<0.001	个0.001
Excess Alcohol	↓<0.001	↓<0.001	↓<0.001	0.168
Low BMI	↓<0.001	↓0.004	↓<0.001	0.158
Comorbidities				
COPD	0.663	0.065	0.844	0.791
Diabetes	↑<0.001	个0.028	↑0.009	↑0.010
TB-related Characteristics				
Extrapulmonary TB (n=8380)	↑<0.001	0.060	↑0.022	$\uparrow 0.005$
Positive AFB Smear (n=7683)	↑<0.001	↑<0.001	↑<0.001	0.179
DR-TB	↑<0.001	↑<0.001	↑<0.001	↑0.002
No. of Contacts (n=8103)	个0.017	个0.007	0.910	0.090
All adverse treatment Outcomes	↓0.001	↓<0.001	0.256	0.308
Treatment Failure	0.976	0.318	0.539	0.525
Abandoned Treatment	↓<0.001	↓0.003	↓0.028	0.789
Died	0.278	↓0.004	0.934	0.283

Note: n indicated in parenthesis for variables with missing data. DR-TB= resistant to any of the TB drugs tested

(i.e. isoniazid, rifampin, pyrazinamide, streptomycin, ethambutol)

^a p values shown for the score test for trend of odds for categorical variables, and for the nonparametric test for

trend across ordered groups, for number of contacts

[†]Trend direction with respect to old age is indicated by arrows preceding the trend p values